Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells - Wikidata - wikimedia - TriplyDB

Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells

Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells

http://www.wikidata.org/entity/Q37376981

about

Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents Choline metabolism-based molecular diagnosis of cancer: an update ROS homeostasis and metabolism: a critical liaison for cancer therapy Dynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro data Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism Effects of lovastatin on breast cancer cells: a proteo-metabonomic study.Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells Effect of dietary sodium restriction on human urinary metabolomic profiles.Glycolysis inhibitor screening identifies the bis-geranylacylphloroglucinol protonophore moronone from Moronobea coccinea.Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer.Phosphorylation of serine palmitoyltransferase long chain-1 (SPTLC1) on tyrosine 164 inhibits its activity and promotes cell survival.Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells.ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.Chronic myeloid leukemia stem cells and developing therapies.Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma.Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia.Ameliorating effect of Kalpaamruthaa on altered energy metabolism in BCR-ABL(+) cell line induced leukemic mouse model.Triomics Analysis of Imatinib-Treated Myeloma Cells Connects Kinase Inhibition to RNA Processing and Decreased Lipid Biosynthesis.The unfolded protein response in glioblastomas: targetable or trouble?Exploring cancer metabolism using stable isotope-resolved metabolomics (SIRM).S6K1 determines the metabolic requirements for BCR-ABL survival.Bezielle (BZL101)-induced oxidative stress damage followed by redistribution of metabolic fluxes in breast cancer cells: a combined proteomic and metabolomic study.Metabolic assessment of a novel chronic myelogenous leukemic cell line and an imatinib resistant subline by H NMR spectroscopy.Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production.Quantitative- and phospho-proteomic analysis of the yeast response to the tyrosine kinase inhibitor imatinib to pharmacoproteomics-guided drug line extension.Association of DJ-1/PTEN/AKT- and ASK1/p38-mediated cell signalling with ischaemic cardiomyopathy.Investigations on the cell metabolomics basis of multidrug resistance from tumor cells by ultra-performance liquid chromatography-mass spectrometry.NMR-Based Metabolomic Analysis of Normal and Inflamed Gut.Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML).

P2860

Q26740567-51768939-94B7-4807-AD52-273C957FDC4A Q27024079-31EDD4C3-2A70-4FFF-8FBD-355F9E292DF3 Q28080316-97697557-0F90-4E32-93F8-4FC3076121B9 Q28478542-78D980A3-7DBB-4554-93B4-436B30BCF149 Q33738391-9B170A51-BFFA-4445-B91C-75FE82FF0C96 Q33889477-AB4AE31C-3E60-4CFC-8812-41A82F674E3E Q33971155-E1451C17-638A-4B4A-B480-515D4D952490 Q34988108-F38DE232-4085-421C-91F7-B62D015A4B73 Q35817074-5771215B-DC83-457E-B05B-BB617FDD38F1 Q36494623-07D4F5DE-5C6C-47B0-A0BB-D88B5586262B Q36903072-7847FE85-BE06-4682-A851-30DB3E4B3CA6 Q36928954-967C72E1-D331-41C3-A4FD-6734914150F7 Q37161696-76193799-13C5-4A56-8825-C74F0F3AAE23 Q37379680-F85EC312-7066-4C90-B2A9-588663EFD95D Q37400663-377A7AA9-F724-42CD-971A-4D394DC9C14D Q37836936-6389247E-6B25-4DDA-A0F6-7562D38E9B73 Q37871191-0CF72314-7501-4582-9A01-21FB34806BC6 Q38707129-F806594C-60EA-49CA-99BE-58686C0D5880 Q38761736-3AF28875-F362-489B-8219-43F0D9104378 Q38762570-D0F25EEB-7E3C-419D-8861-F84418C2D551 Q38830422-16628AE6-6062-44AA-B2EC-5C4E8E736BBF Q38970037-61C2A52B-DCA6-4019-9E97-85702C0F7D8C Q39358317-7D83CAB5-0D98-4D49-A583-7EEE5EEBFC75 Q39385165-438164F8-3288-4375-B8DC-994A0D642170 Q39555290-C37DAFCE-51BA-466D-A959-916DFED38C1D Q39672888-653A99B7-265E-494D-AF9A-AE6B0EE1D50E Q40015371-EE367282-0412-4295-B6D6-D3673195FFA2 Q42586969-ABB44152-375C-45CF-A816-12F6D35BE8B1 Q46634695-AC8412AF-15D3-41E5-9D68-3499B1DA2D95 Q51662791-97F1A5C3-8FA9-4F6F-8D82-F154C7CDCF2C Q53091002-0E8A347B-BDED-4D36-808C-BF98147B6479 Q54229178-34C0A638-0006-4420-B89F-BF5B77B20CB7

P2860

Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells

http://www.wikidata.org/entity/Q37376981

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells

@en

Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.

@nl

type

label

Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells

@en

Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.

@nl

prefLabel

Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells

@en

Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.

@nl

P1433

Q37376981-7831035A-DADE-4CF2-96A2-55DD1B78F65F

P1476

Q37376981-6F0DCF09-5447-46A2-A17E-8CA0FF83F1B7

P2093

Q37376981-0D629128-B341-4ACB-AD5F-856AB02DF053

Q37376981-716DEA3D-514F-426B-A0C6-17F497C08063

Q37376981-9770878D-CBA4-470C-B24F-9240277D1740

Q37376981-B7946E1F-CB41-42F9-90C3-C7C2BCE3841E

Q37376981-BACF40AE-9467-44D4-A1C2-CFE336397877

Q37376981-C2321935-7989-4DF0-A1CE-0234A18BFDC4

Q37376981-C9896583-BC30-405A-8B94-10E2D603ED31

Q37376981-C9C7C3C3-4DB2-4B78-9CAD-0DD93E787807

Q37376981-DDA1FDA9-DB5D-4C78-B97B-F2A8EA2416C4

P2860

Q37376981-0AD705D2-01F5-4FF9-BAFA-A0E9455B9378

Q37376981-1BE7A2CD-6A85-4007-B3CE-388193C25FF3

Q37376981-202B7CE9-DF49-4525-85E4-E4F0F8B19FB0

Q37376981-22078F5E-3A7F-468B-89D0-236BDA4F11AD

Q37376981-275256D5-0C7A-4623-A0A8-056CE88BE163

Q37376981-2B034248-BC67-46FE-8B07-AACB4D90CD96

Q37376981-2F47C6BC-387D-4CE8-A345-EFD8BAC99E5E

Q37376981-2FABB8F4-7E8A-42EF-8027-0FE8C8C6670C

Q37376981-3402640F-09B7-4045-B7EA-2DB2469215C2

Q37376981-35537547-B1F2-480E-9F36-29005B3B84A8

P304

Q37376981-FA880042-4A50-49E2-B11F-3E9C10331FE9

P31

Q37376981-EDD0320C-F8F9-4995-BEC3-C64DF522C920

P356

Q37376981-7843D502-358E-4751-9D5F-0B5F9BBCF551

P407

Q37376981-41E82B26-0E29-4407-B6E6-2C5E829D4654

P433

Q37376981-58E3C470-7876-4428-8F0D-D10022D19863

P478

Q37376981-41F136CF-8BC6-4854-A374-7CA9531FE911

P577

Q37376981-BBCC0117-A30D-47D4-8B33-297C2C502968

P5875

Q37376981-8E4B3A53-0957-4078-8C14-281A87266E5E

P698

Q37376981-2FD3AF66-C078-4B28-8D15-37FC111EFC35

P921

Q37376981-995BA520-0E0D-4586-AE61-30915ECF9E8A

P932

Q37376981-83442CDC-57A2-4BEE-9275-9C572B4EB4CC

P356

J.1476-5381.2009.00345.X

P1433

British Journal of Pharmacology

P1476

Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells

@en

P2093

Dieter Leibfritz

http://www.w3.org/2001/XMLSchema#string

Douglas J Kominsky

http://www.w3.org/2001/XMLSchema#string

Jaimi L Brown

http://www.w3.org/2001/XMLSchema#string

Jelena Klawitter

http://www.w3.org/2001/XMLSchema#string

Jost Klawitter

http://www.w3.org/2001/XMLSchema#string

Junia V Melo

http://www.w3.org/2001/XMLSchema#string

Natalie J Serkova

http://www.w3.org/2001/XMLSchema#string

S Gail Eckhardt

http://www.w3.org/2001/XMLSchema#string

Uwe Christians

http://www.w3.org/2001/XMLSchema#string

P2860

On the Origin of Cancer Cells

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Regulation of glial metabolism studied by 13C-NMR.

Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture.

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

Applications of magnetic resonance in model systems: cancer therapeutics

Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway.

The molecular biology of chronic myeloid leukemia.

Active transport of imatinib into and out of cells: implications for drug resistance.

P304

588-600

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1476-5381.2009.00345.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

158

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26725794

http://www.w3.org/2001/XMLSchema#string

P698

19663881

http://www.w3.org/2001/XMLSchema#string

P921

P932

2757699

http://www.w3.org/2001/XMLSchema#string